A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105).

Jessica Mezzanotte-SharpeAnne ONeillIngrid A MayerCarlos L ArteagaXiming J YangLynne I WagnerDavid CellaNeal J MeropolR Katherine AlpaughThomas J SaphnerRobert E SwaneyKaren L HoelzerWilliam J GradisharVandana G AbramsonP Kothai SundaramShamim Z JilaniEdith A PerezNancy U LinMohammad JahanzebAntonio C WolffGeorge W SledgeSonya A Reid

Published in: Breast cancer research and treatment (2024)

NCT00520975.

Keyphrases

phase iii
metastatic breast cancer
double blind
placebo controlled
clinical trial
open label
phase ii
papillary thyroid
study protocol
squamous cell
locally advanced
radiation therapy
squamous cell carcinoma
lymph node metastasis
chemotherapy induced